StockData
INSMED Inc logo

INSMED Inc (INSM) stock

INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30136% above fair value
$144.46+24.66 (+20.58%)

Close on Nov 19, 2026Market cap $31.69BP/E –Yield –

Insmed free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Insmed's free cash flow for the twelve months ending Sep 30, 2026 was -$627.58M. For fiscal 2025 it was -$967.58M. The highest annual figure on record is -$7.72M in fiscal 2010.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$967.58M–
FY2024Dec 31, 2024-$705.81M–
FY2023Dec 31, 2023-$549.54M–
FY2022Dec 31, 2022-$410.32M–
FY2021Dec 31, 2021-$370.59M–
FY2020Dec 31, 2020-$225.59M–
FY2019Dec 31, 2019-$292.92M–
FY2018Dec 31, 2018-$271.07M–
FY2017Dec 31, 2017-$162.62M–
FY2016Dec 31, 2016-$150.91M–
FY2015Dec 31, 2015-$104.15M–
FY2014Dec 31, 2014-$69.77M–
FY2013Dec 31, 2013-$47.49M–
FY2012Dec 31, 2012-$31.30M–
FY2011Dec 31, 2011-$31.18M–
FY2010Dec 31, 2010-$7.72M–
FY2009Dec 31, 2009-$11.01M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$42.09M–
Q2 FY2026Jun 30, 2026-$95.09M–
Q1 FY2026Mar 31, 2026-$226.22M–
Q4 FY2025Dec 31, 2025-$264.19M–
Q3 FY2025Sep 30, 2025-$222.18M–
Q2 FY2025Jun 30, 2025-$209.05M–
Q1 FY2025Mar 31, 2025-$272.16M–
Q4 FY2024Dec 31, 2024-$202.75M–
Q3 FY2024Sep 30, 2024-$184.61M–
Q2 FY2024Jun 30, 2024-$129.74M–
Q1 FY2024Mar 31, 2024-$188.71M–
Q4 FY2023Dec 31, 2023-$132.97M–
Q3 FY2023Sep 30, 2023-$139.19M–
Q2 FY2023Jun 30, 2023-$127.68M–
Q1 FY2023Mar 31, 2023-$149.70M–
Q4 FY2022Dec 31, 2022-$107.84M–
Q3 FY2022Sep 30, 2022-$90.41M–
Q2 FY2022Jun 30, 2022-$105.21M–
Q1 FY2022Mar 31, 2022-$106.86M–
Q4 FY2021Dec 31, 2021-$85.27M–
Q3 FY2021Sep 30, 2021-$76.93M–
Q2 FY2021Jun 30, 2021-$78.93M–
Q1 FY2021Mar 31, 2021-$129.46M–
Q4 FY2020Dec 31, 2020-$67.73M–
Q3 FY2020Sep 30, 2020-$59.42M–
Q2 FY2020Jun 30, 2020-$37.83M–
Q1 FY2020Mar 31, 2020-$60.61M–
Q4 FY2019Dec 31, 2019-$57.44M–
Q3 FY2019Sep 30, 2019-$66.96M–
Q2 FY2019Jun 30, 2019-$90.64M–
Q1 FY2019Mar 31, 2019-$77.88M–
Q4 FY2018Dec 31, 2018-$73.19M–
Q3 FY2018Sep 30, 2018-$67.34M–
Q2 FY2018Jun 30, 2018-$57.76M–
Q1 FY2018Mar 31, 2018-$72.78M–
Q4 FY2017Dec 31, 2017-$49.92M–
Q3 FY2017Sep 30, 2017-$38.69M–
Q2 FY2017Jun 30, 2017-$36.68M–
Q1 FY2017Mar 31, 2017-$37.33M–
Q4 FY2016Dec 31, 2016-$58.73M–

More Insmed figures

See a number that looks wrong?